MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inh... MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Show more
Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind...
Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MannKind...
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes program progression DANBURY, Conn. and WESTLAKE...
India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship product for Cipla Ltd. by end of 2025 DANBURY...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0099 | -0.163907284768 | 6.04 | 6.24 | 5.785 | 2893571 | 6.06208107 | CS |
4 | -0.8399 | -12.2256186317 | 6.87 | 6.8832 | 5.785 | 2306051 | 6.28851343 | CS |
12 | -1.1299 | -15.780726257 | 7.16 | 7.62 | 5.785 | 2872227 | 6.65856187 | CS |
26 | 0.2201 | 3.78829604131 | 5.81 | 7.62 | 4.95 | 2581511 | 6.3520228 | CS |
52 | 2.5601 | 73.7780979827 | 3.47 | 7.62 | 3.17 | 2597147 | 5.46306216 | CS |
156 | 2.3101 | 62.0994623656 | 3.72 | 7.62 | 2.49 | 3321983 | 4.40674194 | CS |
260 | 4.3101 | 250.587209302 | 1.72 | 7.62 | 0.8 | 3347005 | 3.98425799 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales